Durata Therapeutics Inc (NASDAQ:DRTX) Investor Investigation of Acquisition by Actavis Plc
An investigation on behalf of investors, who currently hold shares of Durata Therapeutics Inc (NASDAQ:DRTX), was announced concerning whether the takeover of Durata Therapeutics Inc by Actavis plc for $23 per share is unfair to NASDAQ:DRTX stockholders.
View full press release